Sellas shares climbed after its Phase 3 trial of GPS showed a significant survival benefit for patients with acute myeloid leukemia and no new safety concerns. The company plans to discuss an accelerated filing strategy with the FDA and aims to submit an application in 2027.
After 156% surge in a day, this American firm stock rises another 5%. What's driving the biotech share rally?
Published ·

Keep reading
Related stories




